Tweets
Case-control study of 349 autoimmune (ARD) pts (SLE, RA, SSc) & serum assays for anti-neutrophil extracellular trap (aNET)Abs. aNET in 37% SLE assoc w/ APS (OR 3.4) & arterial thrombosis (OR 5.5). aNET in 40% RA assoc w/ ACPA+ (p=0.049) https://t.co/QwvmLAVmg7 https://t.co/VJ7JV5fcZE
Dr. John Cush @RheumNow ( View Tweet )
1 hour 29 minutes ago
Best JAKi? Italian Observational BIRRA Cohort study of 170 #PsA pts Rx w/ UPA or TOFA found no significance in 6 mos (86 vs 78%) or 12 mos (68 v 60%) retention. Persistence lower in pts Concomitant or later csDMARDs. https://t.co/vtSrO9orh4
Dr. John Cush @RheumNow ( View Tweet )
2 hours 59 minutes ago
Canada’s Drug Agency (CDA-AMC) has recommended Gazyva (obinutuzumab) for public reimbursement. This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy https://t.co/TC1MVAShdC https://t.co/flXVmLwGtW
Dr. John Cush @RheumNow ( View Tweet )
18 hours 30 minutes ago
"Courage is resistance to fear, mastery of fear, not absence of fear."
- Mark Twain https://t.co/xyJqiV7biI
Dr. John Cush @RheumNow ( View Tweet )
21 hours 32 minutes ago
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush @RheumNow ( View Tweet )
21 hours 36 minutes ago
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon (IFN-I), drive systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). A recent comprehensive review synthesizes the https://t.co/VaE295a2Ep
Dr. John Cush @RheumNow ( View Tweet )
22 hours ago
Let me give you an example of where there is no gov intervention, and the impact on brand drug pricing.
When a brand manufacturer sells a drug to one of the big 3 drug distributors that control more than 90 pct of their market, those multi hundred billion dollar distributors
Mark Cuban @mcuban ( View Tweet )
22 hours 45 minutes ago
A Practical Approach to Myositis-Specific Antibodies https://t.co/14qow6zhsD
Rheumatology update @aabdogafar ( View Tweet )
23 hours 2 minutes ago
True or False: In a Japanese study of refractory neuropsychiatric SLE, rituximab led to significant improvement in the majority of patients treated. See if you got it right at https://t.co/3F1h89Qrtw https://t.co/vx0ILsZ3WF
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/HExIhebJ4u
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush @RheumNow ( View Tweet )
1 day 16 hours ago
ABA versus HCQ in Palindromic Rheumatism
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. https://t.co/XPP7CSxGad
Dr. John Cush @RheumNow ( View Tweet )
1 day 20 hours ago
